Joshua Halpern

Dr. Joshua Halpern


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2022 in JAMA Internal Medicine
Verified
Journal Article
Open access
PDF file
JDJustin M. Dubin
Justin M. Dubin
EJErin Jesse
Erin Jesse
RFRichard J. Fantus
Richard J. Fantus
NBNelson E. Bennett
Nelson E. Bennett
RBRobert E. Brannigan
Robert E. Brannigan
JHJoshua Halpern
Joshua Halpern
Direct-to-consumer (DTC) online platforms can expand access to health care screenings and prescription medications. These platforms may be particularly advantageous for men’s health issues, such as erectile dysfunction, androgenic alopecia, and male infertility, because stigma may prevent men from seeking in-person evaluation for these issues. Accordingly, DTC men’s health platforms have seen exponential growth even prior to the COVID-19 pandemic, with a 1500% increase in online visits to DTC platforms treating erectile dysfunction from 2017 to 2019.1 Recently, given increased prescriptions for testosterone therapy and associated spending of over $400 million in the US, several new DTC testosterone therapy platforms have emerged.2,3 However, unlike pharmacotherapy for erectile dysfunction and androgenic alopecia, testosterone is a Class III controlled substance associated with increased risk of infertility, polycythemia, and possibly cardiovascular events, with the latter prompting multiple safety communications from the US Food and Drug Administration.4 Given the potential risks of testosterone therapy, we sought to examine whether DTC platforms provide appropriate, guideline-concordant care for testosterone therapy.

8 January 2021 in Sexual Medicine
Verified
Journal Article
Open access
JWJoel J. Wackerbarth
Joel J. Wackerbarth
RFRichard J. Fantus
Richard J. Fantus
ADAnnie Darves-Bornoz
Annie Darves-Bornoz
MHMarah C. Hehemann
Marah C. Hehemann
BHBrian T. Helfand
Brian T. Helfand
JHJoshua Halpern
Joshua Halpern
Background: Direct-to-consumer (DTC) Internet-based prescription and pharmacy platforms offer electronic consultation for evaluation and pharmacologic treatment of erectile dysfunction (ED) without a physical exam or in-person visit, presenting a potentially dramatic shift in care for this condition. Aim: To characterize the extent to which DTC prescribing sites for ED generate traffic and attract individual users. Methods: Using SEMRush, a marketing software platform that provides analytics regarding website traffic, we examined online site visits to 6 major DTC prescribing websites offering ED evaluation and treatment from October 2017 through December 2019. Outcomes: We recorded trends in the number of unique visitors over time, visitor referral patterns, and the proportion of overall visitors to individual sites. Results: During the study period, the total number of unique, quarterly visitors increased by 1,688% from 655,733 in the 4th quarter (Q4) 2017 to over 11 million in Q4 2019. In 2019, there were on average 4,971,674 visits to all sites combined each month. For the 2 largest sites (Hims and Roman), visitors predominantly reached the site via direct web address (27.3%) or search engine referral (27.3%). Clinical implications: An increasingly large number of potential patients are utilizing DTC prescribing platforms for the diagnosis and treatment of ED, which do not require physical exams or treatment of other comorbid conditions. Strength & Limitations: Demonstrates high demand for ED DTC prescribing services using independent market research software and characterizes the number of visits for the first time. Limitations include the lack of individual demographics and lack of information regarding what proportion of unique visits lead to evaluation and treatment using the services. Conclusion: The dramatic increase in visits to DTC prescribing sites that treat ED represents a paradigm shift in ED care, and it is imperative that clinicians and researchers work to understand how patients utilize online telemedicine, the safety and efficacy of online management of ED, and the potential downstream implications of its widespread use.

1 October 2021 in Fertility and Sterility
Verified
Journal Article
Closed access
JLJeremy D. Lai
Jeremy D. Lai
RFRichard J. Fantus
Richard J. Fantus
ACAndrew J. Cohen
Andrew J. Cohen
VWVivian Wan
Vivian Wan
MHMatthew T. Hudnall
Matthew T. Hudnall
JHJoshua Halpern
Joshua Halpern

1 July 2019 in Journal of Urology
Verified
Journal Article
Closed access
JSJonathan E. Shoag
Jonathan E. Shoag
NPNeal Patel
Neal Patel
LPLina Posada
Lina Posada
JHJoshua Halpern
Joshua Halpern
TSTalia Stark
Talia Stark
BEBrian H. Eisner
Brian H. Eisner
Purpose:The rise in opioid related deaths and addiction has been linked to physician prescribing. Opioids are commonly prescribed to patients with renal colic due to nephrolithiasis. The aim of thi...

1 February 2021 in Urologic Clinics of North America
Verified
Journal Article
Closed access
ADAnnie Darves-Bornoz
Annie Darves-Bornoz
EPEvan Panken
Evan Panken
RBRobert E. Brannigan
Robert E. Brannigan
JHJoshua Halpern
Joshua Halpern

1 June 2021 in Fertility and Sterility
Verified
Journal Article
Closed access
RFRichard J. Fantus
Richard J. Fantus
JHJoshua Halpern
Joshua Halpern